{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:13:55Z","timestamp":1793938435203,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.apjo.2025.100245","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:50:16Z","timestamp":1758070216000},"page":"100245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence"],"prefix":"10.1016","volume":"15","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2025.100245_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.preteyeres.2011.02.003","article-title":"Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models","volume":"30","author":"Bernstein","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100245_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jocn.2009.04.002","article-title":"Non-arteritic anterior ischaemic optic neuropathy: a review and update","volume":"16","author":"Kerr","year":"2009","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.apjo.2025.100245_bib3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41433-023-02716-4","article-title":"NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies","volume":"38","author":"Martin-Gutierrez","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.apjo.2025.100245_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.preteyeres.2008.11.002","article-title":"Ischemic optic neuropathy","volume":"28","author":"Hayreh","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100245_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.120.5.601","article-title":"Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy","volume":"120","author":"Mojon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib6","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.2147\/IJGM.S364051","article-title":"Vision-Related quality of life and association between retinal parameters in patients with Non-Arteritic anterior ischemic optic neuropathy","author":"Su","year":"2022","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.apjo.2025.100245_bib7","doi-asserted-by":"crossref","unstructured":"Li Y., M. Sun, B. Chen, et al. Optic disc edema with decreased visual function after high-altitude exposure. 2024.","DOI":"10.21203\/rs.3.rs-4763281\/v1"},{"key":"10.1016\/j.apjo.2025.100245_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/bjophthalmol-2016-309250","article-title":"Progression of asymptomatic optic disc swelling to non-arteritic anterior ischaemic optic neuropathy","volume":"101","author":"Subramanian","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib9","unstructured":"Gonz\u00e1lez Mart\u00edn-Moro J., I. Contreras, C. Gutierrez-Ortiz, et al. Disc configuration as a risk and prognostic factor in NAION: the impact of cup to disc ratio, disc diameter, and crowding index, Taylor & Francis."},{"key":"10.1016\/j.apjo.2025.100245_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0161-6420(99)90159-8","article-title":"Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy","volume":"106","author":"Salomon","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100245_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247126","article-title":"Risk factors and visual outcome of Non-Arteritic ischemic optic neuropathy (NAION): experience of a tertiary center in Kuwait","volume":"16","author":"Behbehani","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.apjo.2025.100245_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview","volume":"7","author":"Salvetat","year":"2023","journal-title":"Vision"},{"key":"10.1016\/j.apjo.2025.100245_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3329\/bjm.v53i3.75561","article-title":"GLP-1 RA-Semaglutide a game changer drug for management of obesity with and without Diabetes-A narrative review","volume":"35","author":"Islam","year":"2024","journal-title":"Bangladesh J Med"},{"key":"10.1016\/j.apjo.2025.100245_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/biomedicines12061320","article-title":"New developments in pharmacological treatment of obesity and type 2 Diabetes\u2014Beyond and within GLP-1 receptor agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.apjo.2025.100245_bib15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.apjo.2025.100245_bib16","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212585","article-title":"Clinical potential of treatment with semaglutide in type 2 diabetes patients","volume":"8","author":"R\u00f8der","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.apjo.2025.100245_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.apjo.2025.100245_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh","year":"2022","journal-title":"J Invest Med"},{"key":"10.1016\/j.apjo.2025.100245_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s44263-024-00095-w","article-title":"Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using google trends extended for health application programming interface","volume":"2","author":"Raubenheimer","year":"2024","journal-title":"BMC Glob Public Health"},{"key":"10.1016\/j.apjo.2025.100245_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjo.2025.100245_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apjo.2025.100245_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system\u2013A disproportionality analysis","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.apjo.2025.100245_bib23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurjpc\/zwae171","article-title":"Rethinking weight loss treatments as cardiovascular Medicine in obesity, a comprehensive review","volume":"31","author":"Tuccinardi","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.apjo.2025.100245_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/aos.17473","article-title":"Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association","author":"Amini","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.apjo.2025.100245_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.apjo.2025.100245_bib27","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil Med Res"},{"key":"10.1016\/j.apjo.2025.100245_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/17439760.2016.1262613","article-title":"Thematic analysis","volume":"12","author":"Clarke","year":"2017","journal-title":"J Posit Psychol"},{"key":"10.1016\/j.apjo.2025.100245_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/9781119099369.ch27","article-title":"Comprehensive meta-analysis software","author":"Borenstein","year":"2022","journal-title":"Syst Rev Health Res meta-Anal Context"},{"key":"10.1016\/j.apjo.2025.100245_bib30","article-title":"The effect of semaglutide and GLP-1 RAs on risk of Non-Arteritic anterior ischemic optic neuropathy","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-025-03958-4","article-title":"Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association","volume":"25","author":"Ahmadi","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system \u2013 a disproportionality analysis","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.apjo.2025.100245_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib34","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100245_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.apjo.2025.100245_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100245_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.orcp.2025.03.001","article-title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: an emerging pharmacovigilance signal?","author":"Procacci","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.apjo.2025.100245_bib39","series-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish\u2013Norwegian cohort study. medrxiv","author":"Simonsen","year":"2024"},{"key":"10.1016\/j.apjo.2025.100245_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/eye.2014.144","article-title":"Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy","volume":"29","author":"Miller","year":"2015","journal-title":"Eye"},{"key":"10.1016\/j.apjo.2025.100245_bib41","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.3390\/ijms26073050","article-title":"GLP-1 receptor agonists and myocardial perfusion: bridging mechanisms to clinical outcomes","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apjo.2025.100245_bib42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11934-023-01180-7","article-title":"Embracing the pros and cons of the new weight loss medications (Semaglutide, Tirzepatide, Etc.)","volume":"24","author":"Moyad","year":"2023","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.apjo.2025.100245_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.apjo.2025.100245_bib44","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjo.2025.100245_bib45","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjo.2025.100245_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925001124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925001124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:41:25Z","timestamp":1780062085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098925001124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2162098925001124"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100245","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100245"}}